Aerovate
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 51
- Market Cap
- $54.2M
- Introduction
Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was founded by Benjamin T. Dake on July 27, 2018 and is headquartered in Waltham, MA.
Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Aerovate Therapeutics
- Target Recruit Count
- 186
- Registration Number
- NCT05557942
- Locations
- 🇺🇸
UCLA/David Geffen School of Medicine-Pulmonary and Criticial Care, Los Angeles, California, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
🇺🇸Indiana University Health, Indianapolis, Indiana, United States
A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Aerovate Therapeutics
- Target Recruit Count
- 202
- Registration Number
- NCT05036135
- Locations
- 🇺🇸
Tufts Medical Center, Inc., Boston, Massachusetts, United States
🇬🇷AHEPA General Hospital of Thessaloniki, ThessalonÃki, Greece
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States